Breakthrough in Weight Loss: A New Oral Pill Shows Promising Results
A new daily weight loss pill has shown remarkable potential, offering an alternative to injectable treatments like Ozempic. The drug, known as orforglipron, has been found to help users lose an average of almost two stones (12.4kg) over a 72-week period. This significant result comes from a groundbreaking final stage trial that involved a large number of participants.
The study revealed that individuals taking orforglipron experienced not only weight loss but also improvements in various health markers. These included reductions in bad cholesterol, blood fats, and blood pressure. The drug targets the same GLP-1 receptors as popular weight-loss medications such as Ozempic, Wegovy, and Mounjaro, which are known for suppressing appetite and increasing feelings of fullness.
Manufacturers, Eli Lilly, have expressed confidence in the potential of this oral medication. They believe it could be launched on a global scale without supply constraints as early as next year. The company is currently preparing to apply for regulatory approval, marking a crucial step towards making the drug available to the public.
Unlike traditional injections, orforglipron can be stored at room temperature and taken at any time of day, either with or without food. This convenience may make it more appealing to a broader audience, particularly those who prefer not to use injectable treatments. The pill’s ease of production and transportation could also lead to a more affordable option compared to its injectable counterparts.
The 72-week study involved 3,127 adults who were either obese or overweight with weight-related medical conditions. Participants were given either a placebo or one of three doses of orforglipron. All doses resulted in clinically meaningful weight loss, with the highest dose of 36mg leading to an average loss of 27lbs (12.4kg), or 12.4% of their body weight.
Notably, nearly 60% of participants in the highest dose group lost at least 10% of their body weight, while 40% lost at least 15%. In contrast, the placebo group only managed to lose about 0.9% of their body weight over the study period.
Researchers emphasize that the results demonstrate the tablet's 'significant efficacy' and a safety profile similar to existing weight-loss injections. Side effects were generally mild to moderate, with gastrointestinal issues being the most commonly reported. Approximately 33.7% of participants on the highest dose experienced nausea, 25.4% had constipation, and 23.1% suffered from diarrhea. About 10.3% of those on the highest dose discontinued treatment due to adverse events.
The detailed findings of the ATTAIN-1 study will be presented at the European Association for the Study of Diabetes Annual Meeting next month and published in a peer-reviewed journal. This marks an important milestone in the ongoing battle against obesity, which affects over one billion people globally.
Compared to previous studies, where semaglutide led to a 14% weight loss and tirzepatide resulted in a 20% weight loss over the same period, orforglipron shows competitive results. In the UK, two-thirds of adults are either obese or overweight, and more than 5 million people have type-2 diabetes, often linked to lifestyle factors. Estimates suggest that one in ten women already uses weight-loss jabs, highlighting the growing demand for effective solutions.
GLP-1 injections have faced global shortages due to increased popularity, especially among celebrities. The NHS has warned against purchasing these medications from unauthorized sources, emphasizing the importance of safe and regulated access.
As the fight against obesity continues, the introduction of orforglipron offers a promising new tool. With its potential for widespread availability and convenience, it could significantly impact how obesity is managed globally.